Skip to content

The Neuro-epigenetics Biomarkers of Postoperative Delirium in Elderly Patients Undergoing Hip/Knee Replacement

The Neuro-epigenetics Biomarkers of Postoperative Delirium in Elderly Patients Undergoing Hip/Knee Replacement

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04923243
Enrollment
300
Registered
2021-06-11
Start date
2021-11-03
Completion date
2024-06-30
Last updated
2023-08-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Delirium

Brief summary

Introduction: Postoperative delirium (POD), an acute, transient, fluctuating disturbance in attention, cognition, and level of consciousness, is a common (15-53%) postoperative complication, and it is associated with longer hospital stays, worse functional outcomes, higher healthcare costs, and increased mortality. However, at the current time, effective prevention and treatment are not only hampered by lack of knowledge about the neuropathogenesis of POD but also by a lack of biomarkers that could predict individual risk and assess diagnosis and severity of POD. Recent studies have focused on inflammatory markers (IL-1, IL-6, IL-8, IL-10, CRP), Alzheimer's disease-related factors (Tau, Aβ40/42), and nerve injury factors (S100β, NSE), but failed to establishing causality between these markers and POD. Furthermore, these results were contradictory. Previous study of the investigators found that the dysregulation of preoperative microRNA (miR)-146a and miR-181c in cerebrospinal fluid (CSF) and serum was associated with the development and severity of POD. Therefore, the investigators hypothesized these neurimmiRs and other neuro-epigenetics biomarkers might participate in the neuropathogenesis of POD. Purpose: Aims to search for neuro-epigenetics biomarkers to predict and diagnose POD.

Detailed description

Method: 1. Study design: This study is a prospective investigation that searches for neuro-epigenetics biomarkers to predict and diagnose POD. 2. Inclusion criteria / Exclusion Criteria Inclusion criteria: Eligible patients were at least 65 years old and were scheduled to have hip/knee replacement. Exclusion Criteria: 1. a past medical history of neurological or clinically evident neurovascular disease (e.g., Alzheimer's disease, other forms of dementia, stroke); 2. Patients diagnosed with malignant or benign tumors; 3. Mini-Mental State Examination (MMSE) scores of 26 or less; 4. American Society of Anesthesiologists (ASA) score \[a global score that assesses the physical status of patients before surgery, ranging from 1 (normal health) to 5 (moribund)\] greater than 3; 5. a history of alcohol abuse and drug dependence; 6. inability to read or severe visual or auditory deficits; 7. unwillingness to comply with the protocol or procedures.

Interventions

hip/knee replacement

Sponsors

Zhongnan Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
65 Years to 100 Years
Healthy volunteers
No

Inclusion criteria

Eligible patients were at least 65 years old and were scheduled to have hip/knee replacement.

Exclusion criteria

1. a past medical history of neurological or clinically evident neurovascular disease (e.g., Alzheimer's disease, other forms of dementia, stroke); 2. patients diagnosed with malignant or benign tumors; 3. Mini-Mental State Examination (MMSE) scores of 26 or less; 4. American Society of Anesthesiologists (ASA) score greater than 3; 5. a history of alcohol abuse and drug dependence; 6. inability to read or severe visual or auditory deficits; 7. unwillingness to comply with the protocol or procedures.

Design outcomes

Primary

MeasureTime frameDescription
cell-free DNA, cell-free RNA and exosomal RNA level in blood and urinejust before surgeryCell-free DNA, cell-free RNA and exosomal RNA level in blood and urine of the participants were measured by DNA sequencing or RNA sequencing before surgery.
genome-specific difference between POD and non-POD patientsjust before surgeryCompare the exon sequence in blood samples of the participants, as assessed by whole exome sequencing.
candidate cell-free DNA, cell-free RNA and exosomal RNA level in blood and urinepost operative day 1Candidate cell-free DNA, cell-free RNA and exosomal RNA identified in the first outcome were quantified by PCR or RT-PCR on post operative day 1.

Secondary

MeasureTime frameDescription
Delirium subtype assessment - Richmond Agitation-Sedation Scale (RASS)post operative day 1ranging from -5 to +4 points
Delirium assessment - 3-minute Diagnostic Interview for Confusion Assessment Method (3D-CAM)before surgery (from 1 week before to the day before)positive or negative
Delirium severity assessment - Delirium Severity based on 3D-CAM (3D-CAM-S)post operative day 1ranging from 0 to 7 points

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026